Integrating static angle ports and dynamic collimator rotation in volumetric modulated arc therapy for hypofractionated whole breast irradiation in Chinese females: a single-centre dosimetric study

将静态角度端口和动态准直器旋转整合到容积调强弧形治疗中,用于中国女性低分割全乳照射:一项单中心剂量学研究

阅读:3

Abstract

BACKGROUND: Whole breast irradiation remains the standard in breast-conserving therapy for early-stage carcinoma. Conventional RapidArc™ plans, while dosimetrically efficient, are limited by fixed collimator position. This often leads to unnecessary irradiation to adjacent organs at risk (OARs)—particularly the contralateral breast, ipsilateral lung, and cardiac structures—resulting in increased low-dose exposure. These challenges are exacerbated in Chinese female patients due to characteristic anatomical features, such as smaller, crescent-shaped breasts, and closer heart-to-target distances. The novel RapidArc Dynamic™ system provides dynamic collimator rotation and static angle ports, enabling more beam shaping during volumetric modulated arc therapy. This study evaluates the implementation of RapidArc Dynamic™ for whole breast irradiation, comparing its dosimetric performance against conventional RapidArc™ in Chinese female patients. METHODS: Ten patients with early-stage left breast cancer were retrospectively replanned using RapidArc™ and RapidArc Dynamic™ on Eclipse™ (v18.1). All plans employed 6-MV photons on a TrueBeam™ linear accelerator equipped with a Millennium 120-leaf MLC, prescribed to deliver 40 Gy in 15 fractions to breast planning target volume for evaluation. Dosimetric parameters for PTV and OARs were analyzed using Wilcoxon signed-rank test. RESULTS: The results demonstrated that RapidArc Dynamic™ reduced contralateral breast exposure by 5.7% in maximum dose (29.6 Gy vs. 27.9 Gy) and 27.5% in mean dose (4.0 Gy vs. 2.9 Gy). Significant doses reductions in lungs were observed with a 13% lower mean lung dose (4.6 Gy vs. 4.0 Gy). Cardiac sparing improved with 21.6% lower mean heart dose (3.7 Gy vs. 2.9 Gy). CONCLUSIONS: RapidArc Dynamic™ demonstrates significant improvement in OARs sparing, despite anatomical challenges in Chinese female patients. CLINICAL TRIAL NUMBER: Not applicable. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13014-026-02789-x.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。